1. Introduction {#sec0005}
===============

Among cardiovascular (CV) diseases, coronary artery disease (CAD) remains the leading cause of mortality worldwide,[@bib0005], [@bib0010] and in India.[@bib0015], [@bib0020] The burden of CAD is growing remarkably in India which is evident by more than doubling of mortality and disability rates from CAD in the last 30 years.[@bib0025] In line with this fact, the World Health Organization (WHO) has projected a loss of about 237 billion USD with the current encumbrance of CV diseases over a 10-year period (2005--2015), which is 1.5% of India's GDP.[@bib0030]

Though there is enormous evidence available for managing acute CAD patients, the information on long-term outpatient management of stable coronary artery disease (SCAD) patients is less well documented. Principally, all patients with SCAD require life-long supervised interventions, which include; control of modifiable CV risk factors by lifestyle modification and appropriate use of primary and secondary prevention medicines. Moreover, there has been geographical disparity observed in prevalence and control of these risk factors.[@bib0035] Noticeable variations in metabolic (raised triglycerides and low density lipoproteins (LDL), and low high density lipoproteins (HDL)), clinical (visceral obesity characterized by larger waist-to-hip (WH) ratio), and biochemical (insulin resistance, low adiponectin and high C-reactive protein) characteristics of Asian Indian phenotype have been demonstrated.[@bib0040] In addition, CV disease tends to affect people at a younger age in Asian Indians, which has been cause of concern for experts across India and also acknowledged in current India specific SCAD guidelines.[@bib0045], [@bib0050]

Implementing nation-wide policies becomes essential to control CAD that necessitates a comprehensive assessment of various aspects such as disease burden, manifestations, treatment patterns and clinical outcomes. Multiple longitudinal, epidemiological studies may provide valuable insights into these data and form the foundation for healthcare policies and practices. There is, however, relatively little contemporary information available in India on the management of SCAD patients and associated use of evidence-based medications in primary and secondary prevention. Above all, the existing evidence does not refer to SCAD.[@bib0055], [@bib0060]

The Prospe**c**tive Observational **L**ongitudin**a**l **R**eg**i**stry o**f** patients with stable coronary arter**y** disease (CLARIFY) registry was initiated with the aim to achieve information on clinical characteristics and management of SCAD. The registry also intends to study clinical outcomes of these patients and identify the long-term prognostic factors determining the clinical outcomes. In the present paper, we sought to examine trends in CV risk factor prevalence and pattern of use of the appropriate treatment in India compared with rest of the world (ROW) over 5 years using data from the international CLARIFY registry.

2. Methodology {#sec0010}
==============

2.1. Study design {#sec0015}
-----------------

The rationale and study design of CLARIFY registry have been published previously. [@bib0065] The global CLARIFY registry included a total of 32703 analysable patients, among these Indian cohort included 709 (2.2%) patients and remaining 31994 (97.8%) patients comprised the ROW cohort.

2.2. Patient selection: inclusion and exclusion criteria {#sec0020}
--------------------------------------------------------

The SCAD patient eligibility for inclusion in the study were, presence of at least one of the following: coronary stenosis \>50% on coronary angiography; documented myocardial infarction (MI, \>3months ago); chest pain with myocardial ischemia proven using stress electrocardiogram (ECG), stress echocardiography (Echo), or myocardial imaging; history of coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI; performed \>3months ago). The patients excluded were those hospitalized for CV disease (including revascularisation) 3 months prior to enrolment, patients with planned revascularisation, and the patients with conditions anticipated to impede 5-year follow-up (e.g. serious non-CV disease, conditions limiting life expectancy, limited cooperation or legal capacity, or severe CV disease \[advanced heart failure, severe valve disease, history of valve repair/replacement, etc.\]).

2.3. Data collection {#sec0025}
--------------------

The data collected encompassed demographic characteristics; risk factors and lifestyle; medical history; physical examinations; cardiac measurements included heart rate (HR) by pulse palpation and the resting ECG within the previous 6 months, systolic blood pressure (SBP) and diastolic blood pressure (DBP), and ECG rhythm; presenting symptoms; laboratory values (e.g. HbA~1~c, fasting blood glucose, triglycerides, cholesterol, hemoglobin, and serum creatinine, if available); and current medications taken regularly by the patient for ≥7 days before entry in the registry. The available data were again recorded at each visit, annually up to 5 years.

2.4. Ethics {#sec0030}
-----------

The study was performed in accordance with the principles of the Declaration of Helsinki with due approval by the National Research Ethics Service, Isle of Wight, Portsmouth, and Southeast Hampshire Research Ethics Committee, UK. Written informed consent was obtained from all the patients. The study has been registered to ISRCTN with the registration number: ISRCTN43070564.

2.5. Statistical analysis {#sec0035}
-------------------------

Data are summarised as means with standard deviations or medians with interquartile ranges. Categorical data are presented as counts and percentages. Data were analyzed by χ2 tests or Fisher's exact test for categorical and *t*-test or Mann--Whitney *U* test for continuous variables using 2-sided tests at a significance level of 5% using Statistical Analysis Software (version 9.2). The 5-year clinical outcomes were calculated by COX proportional hazard regression model.

3. Results {#sec0040}
==========

The detailed baseline demographic characteristics and medical history of patients in India and ROW have been published previously.[@bib0070]

3.1. Cardiac measurements {#sec0045}
-------------------------

### 3.1.1. 5-year trend in India {#sec0050}

The prevalence of angina has decreased from 27.8% to 11.2% over a 5-year period in India (p \< 0.0001). A persistent decline in mean SBP, DBP and HR measured by pulse palpation was observed over 5 years. However, there was no significant change in mean HR measured by ECG (p = 0.1330).

### 3.1.2. Comparison with ROW {#sec0055}

Though prevalence of angina was similar in India vs ROW at 5-year (11.2% vs 14.5%, *p* = 0.06), grading of angina was different with a greater proportion of patients presenting with Canadian Cardiovascular Society (CCS) class II in India than ROW (85% vs 58.7%, P \< 0.00008) ([Table 1](#tbl0005){ref-type="table"}). At the end of 5 years, the mean HR was significantly more elevated in India; measured by both palpation (73.8 ± 8.9 bpm vs 67.2 ± 9.5 bpm, p \< 0.0001) and ECG (73.2 ± 11.3 bpm vs 66.1 ± 10.1 bpm, *p \<* 0.0001). There was a significant difference in the mean SBP and DBP (128.3 vs. 130.2 mmHg, *p* = 0.01 and 77.7 vs. 76.1 mmHg, *p* = 0.0004, respectively) in patients from India and ROW at 5-year.Table 1Cardiac symptoms and measurements at 5-year.Table 1India (n = 450)ROW (n = 21982)*p-*ValueNn (%)Nn (%)Angina42748 (11.2)215003109 (14.5)0.06Angina CCS class   Class I2 (4.2)804 (25.9)\<0.00008   Class II41 (85.4)1824 (58.7)   Class III5 (10.4)458 (14.7)   Class IV0 (0.0)21 (0.7)CHF42727 (6.3)214873459 (16.1)\<0.0001NYHA class if CHF symptoms   Class II24 (88.9)2770 (80.1)N.A   Class III3 (11.1)635 (18.4)   Class IV0 (0.0)54 (1.6)SBP (mmHg), Mean ± SD371128.3 ± 11.220006130.2 ± 14.80.01DBP (mmHg), Mean ± SD37177.7 ± 6.62000676.1 ± 9.20.0009HR by pulse palpation (bpm), Mean ± SD37173.8 ± 8.91993967.2 ± 9.5\<0.0001HR on ECG (bpm), Mean ± SD17073.2 ± 11.31368266.1 ± 10.1\<0.0001LBBB if ECG available1708 (4.7)13679565 (4.1)0.71ECG Rhythm if ECG available 17013675   Sinus rhythm162 (95.3)12645 (92.5)0.25   Atrial Fibrillation/Flutter7 (4.1)708 (5.2)   Paced rhythm1 (0.6)322 (2.4)[^1][^2][^3]

3.2. Medical therapies {#sec0060}
----------------------

### 3.2.1. 5-year trend in India {#sec0065}

The 5-year trend of some of the guideline-recommended drugs for management of SCAD confirms a significant decrease in the use of β-blocker, aspirin and lipid lowering agents, while the increase in the use of HR-lowering agent ivabradine was observed (Supplementary Fig. 1).

### 3.2.2. Comparison with ROW {#sec0070}

The use of selected CV medications in India and ROW at 5-year is detailed in [Table 2](#tbl0010){ref-type="table"}. The percentage of patients receiving ivabradine was similar in India vs ROW; *p* = 0.07. The use of β-Blockers, lipid-lowering agents and angiotensin-converting enzyme inhibitors in India was significantly lesser than ROW. However, statin use remained similar at 5-year (*p* = 0.22) and the use of thienopyridine (p \< 0.0001), combination of aspirin and another antiplatelet agent (p \< 0.0001), and combination of antiplatelet agent and anticoagulant (p \< 0.0001) were significantly high in India versus ROW ([Table 2](#tbl0010){ref-type="table"}).Table 2Medical therapy at 5-year.Table 2India (n = 450)ROW (n = 21982)*p-*ValueNn (%)Nn (%)Aspirin388281 (72.4)2043516232 (79.4)0.0005Thienopyridine388129 (33.2)204293691 (18.1)\<0.0001Other antiplatelet agents38839 (10.1)204281860 (9.1)0.29Aspirin and another antiplatelet agent388123 (31.7)204383825 (18.7)\<0.0001Oral anticoagulant38850 (12.9)204362214 (10.8)0.11Antiplatelet agent and anticoagulant38842 (10.8)204421154 (5.6)\<0.0001β-Blockers388253 (65.2)20114214705 (71.9)0.002Ivabradine38869 (17.8)204363051 (14.9)0.07Calcium antagonists38896 (24.7)204365743 (28.1)0.08Verapamil or Diltiazem38825 (6.4)20436903 (4.4)0.04ACE inhibitors388147 (37.9)204399635 (47.1)0.0002Angiotensin II receptor blockers388101 (26.0)204385751 (28.1)0.20Lipid-lowering drugs388312 (80.4)2044118039 (88.2)0.0001Statins if on lipid lowering agents312271 (86.9)1803915954 (88.4)0.22Other antianginal agents38871 (18.3)204413170 (15.5)0.08Trimetazidine38830 (7.7)204412412 (11.8)0.009Ranolazine38826 (6.7)20441311 (1.5)0.0001Diuretics38894 (24.2)204346264 (30.7)0.004Other antihypertensive agents38839 (10.1)204361519 (7.4)0.03Digoxin and derivatives38811 (2.8)20436468 (2.3)0.30Amiodarone/Dronedarone3889 (2.3)20436625 (3.1)0.25Other antiarrhythmic3882 (0.5)20435218 (1.1)0.21[^4][^5][^6]

3.3. Risk factors and their control {#sec0075}
-----------------------------------

### 3.3.1. 5-year trend in India {#sec0080}

There was no significant change in the trend of prevalence of risk factors such as overweight and obesity and their control ([Fig. 1](#fig0005){ref-type="fig"}, [Fig. 2](#fig0010){ref-type="fig"}, respectively) from baseline to 5-year in India. The proportion of patients with raised blood pressure and HbA1c \>7% decreased at 5-year compared to baseline (40.5% vs 25.3% and 24% vs 16.4% respectively). The proportion of patients with raised LDL cholesterol did not decrease, while the patients with lowered HDL (41.6% vs 31.6%) decreased significantly in India at 5-year. Moreover, the target of lowered LDL ( \< 1 g/L, 2.6 mmol/L) was improved at 5-year (60.3% vs 73.9%). Significant reduction in the percentage of patients with elevated HR (≥70 bpm) from baseline to 5-year was observed in India. Nevertheless, the control of HR (≤60bpm) remained poor even at 5-year in India (2.6 to 2.1%, *p* = 0.43).Fig. 1**Trends in risk factor distribution in Indian patients over 5** **year period. A) Overweight & obesity:** A) Overweight was defined as body mass index (BMI) ≥23 kg/m^2^ and obesity ≥27.5 kg/m^2^; B) Raised blood pressure: Defined as systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg; C) Raised LDL cholesterol: Defined as (≥0.7 g/L, 1.8 mmol/L) and ≥1 g/l (2.6 mmol/L); D) Lowered HDL: Defined as ≤40 mg/dL, 1.0 mmol/L E) HbA1c \>7% and F) Heart Rate \>70bpm.BMI, Body Mass Index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein;Fig. 1Fig. 2Trends in target achievement in Indian patients over 5-year period A) mean SBP & DBP B) lowered LDL-C) HbA1c D) Heart rate \<60 bpm.bpm, beats per minute; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressureFig. 2

### 3.3.2. Comparison with ROW {#sec0085}

The prevalence of CV risk factors in India compared to ROW is presented in [Table 3](#tbl0015){ref-type="table"}. The proportion of overweight and obese patients was greater in the ROW than India at 5-year. Almost similar percentage of patients had raised LDL (*p* = 0.2) in India vs ROW. Both the Indian and ROW cohort had a similar percentage of patients achieving LDL and HDL control at 5-year. Significant proportion of Indian patients as compared to ROW exhibited elevated HR (66.7% vs 34.7, *p \<* 0.0001), with only few patients achieving HR control in India (2.1% vs 23.6%, *p \<* 0.0004) at 5-year. Similarly, glycaemic control was demonstrated to be poor at 5-year in India (6.4% vs 12.7%, *p* = 0.01) as compared to ROW.Table 3Risk factor prevalence and control at 5-year.Table 3India (n = 450)ROW (n = 21982)*p-*ValueNn (%)Nn (%)**Distribution of risk factors**Overweight, as defined by BMI (kg/m^2^) ≥23,371290 (78.2)1990417736 (89.1)0.0001Obese, as defined by BMI (kg/m^2^) ≥27.5,37199 (26.7)199049979 (50.1)\<0.0001Smoking initiation for former/never smokers at baseline3975 (1.3)18724476 (2.5)NARaised blood pressure, as defined by SBP ≥ 140 and/or DBP ≥ 90 mmHg37194 (25.3)200075831 (29.1)0.06Raised LDL (≥1 g/L, 2.6 mmol/L)16151 (31.7)111643456 (31)0.46Raised LDL (≥0.7 g/L, 1.8 mmol/L),161117 (72.7)111648467 (75.8)0.20Lowered HDL (≤40 mg/dL, 1.0 mmol/L)15549 (31.6)117323160 (26.9)0.11HbA1c ≥ 7%17128 (16.4)60831448 (23.8)0.02HR on palpation ≥70 bpm4832 (66.7)31091078 (34.7)\<0.0001**Targets Achieved**SBP \<140 mmHg and DBP \<90 mmHg in treated hypertensive defined at baseline258183 (70.9)143939731 (67.6)0.14Lowered LDL (\<1 g/L, 2.6 mmol/L),11988 (73.9)86335960 (69)0.15Lowered LDL (\<0.7 g/L, 1.8 mmol/L)11935 (29.4)86332055 (23.8)0.09HbA~1~c \<7%17120 (11.7)60831283 (21.1)0.002HbA~1~c \<6.5%17111(6.4)6083770 (12.7)0.01HR on palpation ≤60 bpm in angina patients481 (2.1)3109734 (23.6)0.0004[^7][^8]

3.4. Clinical outcomes {#sec0090}
----------------------

At 5-years, the number of deaths in both the groups due to CV and non-CV causes, were comparable ([Table 4](#tbl0020){ref-type="table"}). Unstable angina, stroke (fatal or non-fatal), non-fatal MI, non-fatal stroke and major bleeding were significantly higher in ROW than in India. The proportion of patients who underwent coronary angiography, PCI, and any revascularisation were significantly higher in ROW than in India. Hospitalization for CV diseases and coronary heart failure were also significantly higher in ROW patients than in India.Table 4− Clinical outcomes at 5-year for India compared with ROW.Table 4VariableIndia (n = 706)ROW (n = 31672)HR (95% CI)*p-*ValueAll cause death56 (7.9)2488 (7.9)1.06 (0.81, 1.38)0.69Cardiovascular death39 (5.5)1580 (5.0)1.16 (0.84, 1.59)0.37Non-Cardiovascular death17 (2.4)908 (2.9)0.88 (0.54, 1.42)0.60MI (fatal or non-fatal)20 (2.8)1086 (3.4)0.85 (0.55, 1.33)0.48Stroke (fatal or non-fatal)6 (0.8)680 (2.1)0.41 (0.18, 0.91)0.03Cardiovascular death or non-fatal MI46 (6.5)2307 (7.3)0.93 (0.69, 1.24)0.61Cardiovascular death, non-fatal MI/non-fatal stroke49 (6.9)2758 (8.7)0.82 (0.62, 1.09)0.17Non-fatal MI7 (1.0)788 (2.5)0.41 (0.20, 0.87)0.02Non-fatal stroke4 (0.6)527 (1.7)0.35 (0.13, 0.94)0.04Unstable angina54 (7.6)3385 (10.7)0.73 (0.56, 0.95)0.02Major bleeding2 (0.3)444 (1.4)0.21 (0.05, 0.84)0.03Coronary angiography63 (8.9)4566 (14.4)0.63 (0.49, 0.81)0.0003PCI20 (2.8)2120 (6.7)0.43 (0.28, 0.66)0.0002CABG11 (1.6)424 (1.3)1.21 (0.67, 2.20)0.53Revascularisation (PCI or CABG)31 (4.4)2495 (7.9)0.56 (0.40, 0.80)0.006Transient Ischemic Attack18 (2.5)810 (2.6)1.05 (0.66, 1.67)0.84Hospitalization for CHF22 (3.1)1625 (5.1)0.63 (0.41, 0.95)0.03Cardiovascular death, non-fatal MI, non-fatal stroke/revascularisation (PCI/CABG)49 (6.9)2758 (8.7)0.81 (0.61, 1.07)0.13MI (fatal or non-fatal)/revascularisation (PCI/CABG)48 (6.8)3062 (9.7)0.71 (0.54, 0.95)0.02All coronary events: MI (fatal or non-fatal) or revascularisation (PCI/CABG)/unstable angina74 (10.5)5079 (16.0)0.65 (0.52, 0.82)0.0003Cardiovascular hospitalization129 (18.3)9708 (30.7)0.58 (0.49, 0.69)\<0.0001[^9][^10]

4. Discussion {#sec0095}
=============

Five year results of CLARIFY India show varying trends in the prevalence of CV risk factors. The incidence rates of HR \>70 bpm, HbA1c \>7%, and raised blood pressure decreased significantly while overweight and obesity remained same and raised LDL cholesterol (\>1.0 g/L) showed statistically non-significant reduction. Moreover, no improvement in the control of CV risk factors was observed. The majority of patients received evidence-based therapies with some differences. Overall, the results indicate that irrespective of the status of risk factors prevalence and control, and medication use, the long-term prognosis seems to be satisfactory in the CLARIFY Indian population.

The incidence and prevalence of CAD have increased tremendously in India during the last two decades and this change is largely attributable to rapid urbanisation and alterations in lifestyle.[@bib0075] The pattern of risk factors observed in CLARIFY Indian cohort is consistent with that previously observed in earlier studies including INTERHEART study.[@bib0080], [@bib0085], [@bib0090], [@bib0095] The CLARIFY India results demonstrated no change in the prevalence of overweight and obesity in India over 5 years; however, the prevalence was lower than ROW at both baseline and at 5-year. These results are consistent with findings from the systematic analysis describing global trends in body-mass index since 1980 by the Global Burden of Metabolic Risk Factor of Chronic Diseases Collaborating Group.[@bib0100] On the contrary, an epidemiological study from India reported increase in obesity and truncal obesity.[@bib0055], [@bib0105] Beyond everything, this study primarily highlights the need for better patient and physician education regarding lifestyle improvements and the essential primary and secondary prevention medications.

Despite a slight decrease in mean HR observed at 5-year, a persistently elevated HR (≥70 bpm) from baseline at 5-year has been observed in CLARIFY India population. In patients with suspected and established CAD, an elevated HR is an independent predictor of CV events.[@bib0110], [@bib0115] In view of increasing prognostic value of elevated HR, several guidelines recommend pharmacological HR reduction as an important part of disease management including the recent Indian SCAD guidelines.[@bib0055] Besides β-blockers and non-dihydropyridine calcium channel inhibitors, I*f* inhibitors that block the I*f* current in a sinoatrial node may have a role in therapeutic HR management and angina control. At 5-year, although more than half of patients with SCAD were treated with β-blockers (65.2%), almost 66.7% had resting HR ≥ 70 bpm. These findings imply that patients on β-blockers are not adequately controlled to achieve a target HR ≤ 60 bpm. The results are in line with the baseline results of CLARIFY; wherein 69% patients received β-blocker and about 82% patients had resting HR ≥ 70 bpm.[@bib0070] The observed reduction in the percentage of patients with resting HR ≥ 70 bpm at 5-year (66.7%) from baseline (82%) may be attributed to increasing use of HR-lowering medication like ivabradine (5.4% to 17.8%, *p \<* 0.0001). However, exploratory statistical analysis with adequate power to detect such impact is required to make a definitive conclusion.

The analysis of the medications at 5-year revealed slightly lower use of aspirin and β-blockers in India than ROW, however, this is accompanied by the higher use of thienopyridines and dual antiplatelet agents. Moreover, the 5-year trend in India showed a decrease in some guideline-recommended agents, such as β-blockers (\<5% decrease), aspirin, and lipid lowering agents. Low use of β-blockers may be attributed to intolerance to them[@bib0120] and low aspirin use could be due to increased usage of other antiplatelet agents. In patients intolerant to β-blockers, ivabradine may be prescribed, which has been recently recommended by clinical practice guidelines as well.[@bib0125] Moreover, use of ivabradine is also supported by evidence that the addition of ivabradine to optimal preventive therapy further reduces the risk of coronary events such as hospitalization for MI by 36% and revascularisation by 30%, particularly in a subgroup of patients with elevated resting HR.[@bib0130]

The clinical outcomes in this study are in line with the findings from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial that shows optimal medical therapy alone to be effective in reducing the cardiac events. However, the risk factors reduction has remained lower than expected in the present study.[@bib0135] The study exhibits inherent selection bias owing to the voluntary enrolment of patients by physicians. Patients' enrolment only at urban centres also contributed so-called urban bias. Despite these limitations, a large number of participating countries is the major strength of the registry, which facilitates generalisation of results.

5. Conclusion {#sec0100}
=============

The 5-year trend of CLARIFY India registry indicates varying trends in the prevalence of CV risk factors like HR \>70 bpm, HbA1c \>7%, and raised blood pressure and raised LDL cholesterol. The results also suggest that the risk factors are inadequately controlled. Though, there are few favorable changes in the pattern of receiving guideline-recommended therapy, systematic approaches to improve control of all modifiable risk factors and increase the long-term use of essential primary and secondary prevention medications are required in current clinical practice. The same has been emphasized in the latest Indian guidelines for the management of SCAD.
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[^1]: Values represent n (%) unless specified.

[^2]: N represents patients with data available.

[^3]: CCS, Canadian cardiovascular society; CHF, congestive heart failure; DBP, diastolic blood pressure; HR, heart rate; LBBB, left bundle branch block; NYHA, New York heart association; SBP, systolic blood pressure.

[^4]: Values represent n (%).

[^5]: N represents patients with data available.

[^6]: ACE, angiotensin converting enzyme.

[^7]: Values represent n (%) unless specified.

[^8]: BMI, body mass index; DBP, diastolic blood pressure; HbA~1~c, glycosylated haemoglobin; HDL, high-density lipoprotein; HR, heart rate; LDL, low-density lipoprotein.

[^9]: Values represent n (%) unless specified.

[^10]: CABG, coronary artery bypass surgery; CHF, congestive heart failure; MI, myocardial infraction; PCI, percutaneous coronary intervention.
